NDA.FI

15.87

+0.13%↑

DIM

156.3

+3.17%↑

BKT

14.195

-0.14%↓

FCFS

218.12

+1.89%↑

RAND

25.23

+1.65%↑

NDA.FI

15.87

+0.13%↑

DIM

156.3

+3.17%↑

BKT

14.195

-0.14%↓

FCFS

218.12

+1.89%↑

RAND

25.23

+1.65%↑

NDA.FI

15.87

+0.13%↑

DIM

156.3

+3.17%↑

BKT

14.195

-0.14%↓

FCFS

218.12

+1.89%↑

RAND

25.23

+1.65%↑

NDA.FI

15.87

+0.13%↑

DIM

156.3

+3.17%↑

BKT

14.195

-0.14%↓

FCFS

218.12

+1.89%↑

RAND

25.23

+1.65%↑

NDA.FI

15.87

+0.13%↑

DIM

156.3

+3.17%↑

BKT

14.195

-0.14%↓

FCFS

218.12

+1.89%↑

RAND

25.23

+1.65%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Atidarymo kaina

1.036 -4.43

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.034

Max

1.062

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	77M
Ankstesnė atidarymo kaina	5.47
Ankstesnė uždarymo kaina	1.036

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 23:08; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 23:07; UTC

Uždarbis

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:20; UTC

Uždarbis

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026-04-30 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026-04-30 23:27; UTC

Rinkos pokalbiai

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026-04-30 23:22; UTC

Uždarbis

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026-04-30 23:20; UTC

Rinkos pokalbiai

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026-04-30 22:52; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:33; UTC

Uždarbis

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026-04-30 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026-04-30 22:05; UTC

Uždarbis

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026-04-30 21:57; UTC

Uždarbis

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026-04-30 21:55; UTC

Uždarbis

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026-04-30 21:53; UTC

Uždarbis

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.